Company profile
Exagen Inc.
NASDAQ: XGN · Healthcare · Medical - Diagnostics & Research
#399 of 1,418 Healthcare companies by revenue65th-percentile growth
EA Score
55CFH 49DQ 55GM 71SS 58
v0.1 · 65/100 weight · provisional
↑ growth stability, workforce scale · ↓ return on equity, listing tenure
Methodology →Revenue TTM
$68.4M
Rev growth YoY (TTM)
+20.6%
Net income (FY)
-$20.0M
Employees
216
as of 2026-08-18
Market cap
$159.9M
as of 2026-08-18
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$66.6M$66.6M2025
Net income-$20.0M-$20.0M2025
Operating income-$14.1M-$14.1M2025
Total assets$58.0M$58.0M2025
Liabilities$40.6M$40.6M2025
Equity$17.4M$17.4M2025
Revenue trend
FY2019 – FY2025 · USD
FY19
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Reportable100%
By geography
Not disclosed.
The read
What is Exagen Inc.’s revenue?
Exagen Inc. booked $66.6M in FY2025 revenue, growing 20% year over year — faster than most Healthcare companies we track, at a -30.0% net margin.
Peers · Healthcare
Kura Oncology, Inc.39DPraxsyn Corporation——Pro-Dex, Inc.86AAytu BioPharma, Inc.53DEnanta Pharmaceuticals, Inc.55CCosmos Health Inc.55CNeighbors
San Diego →Key facts
CEOJohn Aballi
SectorHealthcare
IndustryMedical - Diagnostics & Research
HeadquartersVista, CA
ExchangeNASDAQ: XGN
Employees216
IPO date2019-09-19
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.